Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(11):1395–1397. doi: 10.1038/bjc.1997.568

Combined inhibition of topoisomerases I and II--is this a worthwhile/feasible strategy?

P A Vasey, S B Kaye
PMCID: PMC2228166  PMID: 9400932

Full text

PDF
1395

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baguley B. C. DNA intercalating anti-tumour agents. Anticancer Drug Des. 1991 Feb;6(1):1–35. [PubMed] [Google Scholar]
  2. Beck W. T. Unknotting the complexities of multidrug resistance: the involvement of DNA topoisomerases in drug action and resistance. J Natl Cancer Inst. 1989 Nov 15;81(22):1683–1685. doi: 10.1093/jnci/81.22.1683. [DOI] [PubMed] [Google Scholar]
  3. Bertrand R., O'Connor P. M., Kerrigan D., Pommier Y. Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eur J Cancer. 1992;28A(4-5):743–748. doi: 10.1016/0959-8049(92)90107-d. [DOI] [PubMed] [Google Scholar]
  4. D'Arpa P., Beardmore C., Liu L. F. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res. 1990 Nov 1;50(21):6919–6924. [PubMed] [Google Scholar]
  5. Dancey J., Eisenhauer E. A. Current perspectives on camptothecins in cancer treatment. Br J Cancer. 1996 Aug;74(3):327–338. doi: 10.1038/bjc.1996.362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Del Bino G., Lassota P., Darzynkiewicz Z. The S-phase cytotoxicity of camptothecin. Exp Cell Res. 1991 Mar;193(1):27–35. doi: 10.1016/0014-4827(91)90534-2. [DOI] [PubMed] [Google Scholar]
  7. Eng W. K., McCabe F. L., Tan K. B., Mattern M. R., Hofmann G. A., Woessner R. D., Hertzberg R. P., Johnson R. K. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Mol Pharmacol. 1990 Oct;38(4):471–480. [PubMed] [Google Scholar]
  8. Ferguson P. J., Fisher M. H., Stephenson J., Li D. H., Zhou B. S., Cheng Y. C. Combined modalities of resistance in etoposide-resistant human KB cell lines. Cancer Res. 1988 Nov 1;48(21):5956–5964. [PubMed] [Google Scholar]
  9. Giovanella B. C., Stehlin J. S., Wall M. E., Wani M. C., Nicholas A. W., Liu L. F., Silber R., Potmesil M. DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts. Science. 1989 Nov 24;246(4933):1046–1048. doi: 10.1126/science.2555920. [DOI] [PubMed] [Google Scholar]
  10. Gottlieb J. A., Luce J. K. Treatment of malignant melanoma with camptothecin (NSC-100880). Cancer Chemother Rep. 1972 Feb;56(1):103–105. [PubMed] [Google Scholar]
  11. Gupta R. S., Gupta R., Eng B., Lock R. B., Ross W. E., Hertzberg R. P., Caranfa M. J., Johnson R. K. Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer Res. 1988 Nov 15;48(22):6404–6410. [PubMed] [Google Scholar]
  12. Hsiang Y. H., Liu L. F. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 1988 Apr 1;48(7):1722–1726. [PubMed] [Google Scholar]
  13. Kano Y., Suzuki K., Akutsu M., Suda K., Inoue Y., Yoshida M., Sakamoto S., Miura Y. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer. 1992 Feb 20;50(4):604–610. doi: 10.1002/ijc.2910500420. [DOI] [PubMed] [Google Scholar]
  14. Karato A., Sasaki Y., Shinkai T., Eguchi K., Tamura T., Ohe Y., Oshita F., Nishio M., Kunikane H., Arioka H. Phase I study of CPT-11 and etoposide in patients with refractory solid tumors. J Clin Oncol. 1993 Oct;11(10):2030–2035. doi: 10.1200/JCO.1993.11.10.2030. [DOI] [PubMed] [Google Scholar]
  15. Kaufmann S. H. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res. 1991 Feb 15;51(4):1129–1136. [PubMed] [Google Scholar]
  16. Kim R., Hirabayashi N., Nishiyama M., Jinushi K., Toge T., Okada K. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int J Cancer. 1992 Mar 12;50(5):760–766. doi: 10.1002/ijc.2910500516. [DOI] [PubMed] [Google Scholar]
  17. Lefevre D., Riou J. F., Ahomadegbe J. C., Zhou D. Y., Benard J., Riou G. Study of molecular markers of resistance to m-AMSA in a human breast cancer cell line. Decrease of topoisomerase II and increase of both topoisomerase I and acidic glutathione S transferase. Biochem Pharmacol. 1991 Jun 15;41(12):1967–1979. doi: 10.1016/0006-2952(91)90138-u. [DOI] [PubMed] [Google Scholar]
  18. Masuda N., Fukuoka M., Kudoh S., Matsui K., Kusunoki Y., Takada M., Nakagawa K., Hirashima T., Tsukada H., Yana T. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. J Clin Oncol. 1994 Sep;12(9):1833–1841. doi: 10.1200/JCO.1994.12.9.1833. [DOI] [PubMed] [Google Scholar]
  19. Matsuo K., Kohno K., Takano H., Sato S., Kiue A., Kuwano M. Reduction of drug accumulation and DNA topoisomerase II activity in acquired teniposide-resistant human cancer KB cell lines. Cancer Res. 1990 Sep 15;50(18):5819–5824. [PubMed] [Google Scholar]
  20. Moertel C. G., Schutt A. J., Reitemeier R. J., Hahn R. G. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep. 1972 Feb;56(1):95–101. [PubMed] [Google Scholar]
  21. Moscow J. A., Cowan K. H. Multidrug resistance. J Natl Cancer Inst. 1988 Mar 2;80(1):14–20. doi: 10.1093/jnci/80.1.14. [DOI] [PubMed] [Google Scholar]
  22. Oshita F., Noda K., Nishiwaki Y., Fujita A., Kurita Y., Nakabayashi T., Tobise K., Abe S., Suzuki S., Hayashi I. Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer. J Clin Oncol. 1997 Jan;15(1):304–309. doi: 10.1200/JCO.1997.15.1.304. [DOI] [PubMed] [Google Scholar]
  23. Perez-Soler R., Glisson B. S., Lee J. S., Fossella F. V., Murphy W. K., Shin D. M., Hong W. K. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol. 1996 Oct;14(10):2785–2790. doi: 10.1200/JCO.1996.14.10.2785. [DOI] [PubMed] [Google Scholar]
  24. Pommier Y. DNA topoisomerase I and II in cancer chemotherapy: update and perspectives. Cancer Chemother Pharmacol. 1993;32(2):103–108. doi: 10.1007/BF00685611. [DOI] [PubMed] [Google Scholar]
  25. Sugimoto Y., Tsukahara S., Oh-hara T., Liu L. F., Tsuruo T. Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res. 1990 Dec 15;50(24):7962–7965. [PubMed] [Google Scholar]
  26. Tan K. B., Mattern M. R., Eng W. K., McCabe F. L., Johnson R. K. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst. 1989 Nov 15;81(22):1732–1735. doi: 10.1093/jnci/81.22.1732. [DOI] [PubMed] [Google Scholar]
  27. Tewey K. M., Chen G. L., Nelson E. M., Liu L. F. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem. 1984 Jul 25;259(14):9182–9187. [PubMed] [Google Scholar]
  28. Tewey K. M., Rowe T. C., Yang L., Halligan B. D., Liu L. F. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science. 1984 Oct 26;226(4673):466–468. doi: 10.1126/science.6093249. [DOI] [PubMed] [Google Scholar]
  29. Tsuruo T., Matsuzaki T., Matsushita M., Saito H., Yokokura T. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol. 1988;21(1):71–74. doi: 10.1007/BF00262744. [DOI] [PubMed] [Google Scholar]
  30. Woessner R. D., Mattern M. R., Mirabelli C. K., Johnson R. K., Drake F. H. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ. 1991 Apr;2(4):209–214. [PubMed] [Google Scholar]
  31. Zhang H., D'Arpa P., Liu L. F. A model for tumor cell killing by topoisomerase poisons. Cancer Cells. 1990 Jan;2(1):23–27. [PubMed] [Google Scholar]
  32. van der Zee A. G., Hollema H., de Jong S., Boonstra H., Gouw A., Willemse P. H., Zijlstra J. G., de Vries E. G. P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res. 1991 Nov 1;51(21):5915–5920. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES